Quanterix

🎙️ Nicholas Ashton discusses how the ALZpath assay on the Quanterix Simoa® platform showed about 95% accuracy in identifying Alzheimer’s disease pathology in the brain when compared to amyloid PET scans. Watch the full webinar discussion to hear more about his research and how blood biomarkers are impacting Alzheimer's diagnosis. https://bit.ly/45SsXEH #Alzheimers #ALZpath #BloodBiomarkers

The approval of Eli Lilly’s Kisunla represents another important milestone in the advancement of Alzheimer’s care. This is the second anti-amyloid monoclonal treatment approved for early-stage Alzheimer’s patients. Blood-based biomarkers, some of which were measured using Quanterix’s Simoa technology, played an important role in the clinical trials demonstrating safety and efficacy. Quanterix remains committed to building a global testing infrastructure to improve the accessibility of these therapies for the millions of patients suffering from Alzheimer’s disease. #Alzheimers #AlzheimersTreatment #BloodBiomarkers

How soon will health networks be able to expand access to blood-based tests for Alzheimer’s pathology? 🧠 Healio recently interviewed Quanterix CEO Masoud Toloue about the latest shifts in Alzheimer’s diagnostics and the steps needed to make new AD testing methods widely available. CEO Toloue emphasized the importance of the p-Tau 217 biomarker for supporting early diagnosis and discussed how the LucentAD test is now commercially available to providers and networks within the United States. Quanterix’s dedicated teams are working diligently to streamline the implementation of these tests. While Lucent Diagnostics is being integrated into various systems and networks across the U.S., Toloue noted he anticipated rapid access and global expansion over the next 18 months. Stay tuned for more updates as we continue to advance Alzheimer’s diagnostics and improve patient care. https://bit.ly/3URH6wJ #Alzheimers #Healthcare #Diagnostics

Quanterix is excited to grow our cytokine assay menu with Simoa® Advantage PLUS! The recently launched Simoa® IL-17A and IFN-α Multi-Subtype Advantage PLUS Assays bring industry-leading sensitivity that enables quantification, not just detection, of these low abundance cytokines in 95-100% normal blood samples tested. These two assays mark the beginning of our renewed cytokine assay offering, with more single plex and multiplex assays to come! Explore the assays available in Simoa® Advantage PLUS: https://bit.ly/3VLKycB #SimoaAdvantagePLUS #Assays #BiomarkerDetection #Cytokine

New Alzheimer's guidelines advise utilizing biological criteria to diagnose and stage the disease. 🧠 Guidelines published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association® now utilize biological criteria instead of clinical symptoms to diagnose and stage Alzheimer's disease. This shift is motivated by three significant developments in the last few years: 1️⃣ Approval of anti-amyloid drugs targeting disease pathology 2️⃣ Advancements in blood-based biomarkers making diagnosis more accessible 3️⃣ Research indicating imaging and fluid-based biomarkers can be used interchangeably The guidelines highlight biomarkers such as plasma p-tau 217 for diagnosing, staging, prognosticating, and assessing Alzheimer's treatment. They emphasize the importance of these biomarkers in ensuring accurate diagnoses and informed treatment decisions, including eligibility for Aβ-specific therapies and personalized symptomatic treatments. Additionally, the guidelines introduce biomarkers like neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) for detecting Alzheimer's-related biological processes. Previously used in clinical trials, these biomarkers provide clinicians with more tools for making informed treatment decisions for Alzheimer's disease. 📚 Explore the new guidelines: https://bit.ly/3xOIdWm 📰 Read more on the full implications of the study in 360Dx: https://bit.ly/4cm6MJx #Alzheimers #BloodBiomarkers #AlzheimersDiagnosis

As Quanterix continues to celebrate Pride month, we are thrilled to announce and congratulate Wattanak Chhea, the recipient of our first annual Quanterix LGBTQ+ STEM Scholarship, sponsored by Quanterix IT. Wattanak, a junior at UMASS Lowell studying pharmaceutical sciences, has demonstrated outstanding academic excellence and a commitment to advancing diversity in STEM fields. As the brother of one of our Manufacturing employees, Wattanak exemplifies the values we hold dear at Quanterix. We are proud to support his educational journey and look forward to seeing his future achievements. Congratulations, Wattanak!   #PrideMonth #STEMScholarship Jamie Graceffa, ODCP, Alexandra Phillips, Erica Bell

The highly attended webinar featuring Dr. Milena Dumont Milutinovic and Dr. Nicholas Ashton will be available for viewing once more. Join us on July 17 for a webinar replay of "Accelerating drug approval with Simoa® ultrasensitive measurements of biomarkers." This expert-led presentation discusses the role that Simoa® technology plays in biomarker identification and validation and explores more about its impact on drug trials and patient management. Register now to discover the potential of Simoa in neurology, oncology, inflammation, and infectious diseases: https://bit.ly/3VTWw5a #Neurology #Oncology #Biomarkers

Detect multiplex circulating biomarkers at the earliest stages of the disease, even before symptoms start. ⬇️ https://bit.ly/4bh3Koz

We’re excited to share the publication of the first performance recommendations for blood-based biomarker (BBM) tests by CEOi. 🩸 🧠 Given their accessibility and affordability, BBMs have the potential to improve equity in Alzheimer’s care. As advancements in disease-modifying treatments continue, these new standards will help ensure BBM tests provide early and accurate diagnoses, which are crucial for effective patient care. The publication, created by leading experts in the field, is now available in Nature Reviews Neurology. Key points include: ➡️ For use as a confirmatory tool without follow-up amyloid PET or CSF tests, a BBM test should have performance standards equivalent to CSF confirmation tests: a sensitivity and specificity of ~90%. ➡️ For use as a triaging tool before subsequent confirmatory tests, a BBM test should have a sensitivity of ≥90% with a specificity of ≥85% in primary care and ≥75-85% in secondary care. By adhering to these standards, BBM tests are poised to revolutionize Alzheimer’s diagnosis and treatment. Learn more about the CEOi BBM Workgroup and access the manuscript ➡️ https://bit.ly/4chFBzk CEOi - Global CEO Initiative on Alzheimer's Disease #BloodBiomarkers Nature Portfolio #BloodTest #Alzheimers

Join us on June 26 for an impactful webinar that explores the Quanterix Accelerator Laboratory and its full spectrum of services. Hear from Dr. Matthew Havrda of Geisel School of Medicine at Dartmouth as he delves into the role of NLRP3 inflammasome in neurodegenerative diseases and shares how our ultra-sensitive immunoassays can elevate your research. Don’t miss insights from his innovative assays developed with Quanterix and the The Michael J. Fox Foundation for Parkinson's Research. Register today: https://bit.ly/4cvPpFF #ScientificDiscovery #BiomarkerResearch Dartmouth College